Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $6.29

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $6.29.

FULC has been the topic of a number of recent analyst reports. Leerink Partners upgraded Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and increased their price objective for the stock from $4.00 to $12.00 in a research report on Friday, May 23rd. Cantor Fitzgerald raised Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 price target on the stock in a report on Thursday, May 15th. Leerink Partnrs upgraded Fulcrum Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Friday, May 23rd. Finally, Piper Sandler reissued an "overweight" rating and set a $9.00 price objective (up previously from $6.00) on shares of Fulcrum Therapeutics in a report on Thursday, May 29th.

Hedge Funds Weigh In On Fulcrum Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets purchased a new position in shares of Fulcrum Therapeutics during the 4th quarter valued at about $38,000. Jump Financial LLC purchased a new position in shares of Fulcrum Therapeutics during the first quarter worth approximately $30,000. Brooklyn Investment Group lifted its holdings in shares of Fulcrum Therapeutics by 209.7% in the 1st quarter. Brooklyn Investment Group now owns 12,190 shares of the company's stock worth $35,000 after acquiring an additional 8,254 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Fulcrum Therapeutics in the 1st quarter worth approximately $39,000. Finally, Mariner LLC purchased a new stake in shares of Fulcrum Therapeutics in the 4th quarter valued at $78,000. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Trading Up 1.1%

Shares of Fulcrum Therapeutics stock traded up $0.07 on Thursday, reaching $7.00. The stock had a trading volume of 146,358 shares, compared to its average volume of 915,507. The business's 50 day moving average is $6.36 and its two-hundred day moving average is $4.58. Fulcrum Therapeutics has a 1 year low of $2.32 and a 1 year high of $10.13. The company has a market cap of $378.08 million, a P/E ratio of -100.04 and a beta of 2.37.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.01. On average, equities analysts anticipate that Fulcrum Therapeutics will post -0.16 EPS for the current fiscal year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.